Crossmark

Correction to: Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists

Crossref DOI link: https://doi.org/10.1007/s40264-019-00830-5

Published Online: 2019-04-30

Published Print: 2019-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Christensen, Rasmus M. https://orcid.org/0000-0003-0590-6285
Juhl, Christian R. https://orcid.org/0000-0003-3024-4017
Torekov, Signe S. https://orcid.org/0000-0001-6779-0252
License Information

Text and Data Mining valid from 2019-04-30
More Information

Article History

First Online: 30 April 2019

Free to read: This content has been made available to all.